Key points

  • Starling Oncology, Inc. (NASDAQ: STLN) is down 45.97% to $3.62, leaving the Healthcare name with a market capitalisation of $0.36 billion.
  • Volume reached 23,873,174 shares against a 1,380,982 average, or 17.3 times normal turnover.
  • Our SEC Form 4 database shows one insider bought 8 times for $687,745, most recently on Fri Aug 14 2026, while two insiders made 4 disposals worth $2.2 million, most recently on Fri Aug 21 2026.

Shares of Starling Oncology, Inc. fell 45.97% to $3.62, cutting the stock to a market capitalisation of $0.36 billion. Trading volume reached 23,873,174 shares against an average of 1,380,982, or 17.3 times the usual pace. The price now sits 27% of the way up a 52-week range that runs from $2.32 to $7.13.

What Is Moving Starling Oncology, Inc. Today?

The freshest dated item on the tape is a MarketBeat report from roughly 19 hours ago noting that Lake Street Capital lowered its price target on Oncology Institute (NASDAQ: STLN). That followed a dense cluster of coverage four days earlier, when the company released quarterly results. MarketBeat reported that the quarterly earnings missed expectations by $0.06 in EPS, while Yahoo Finance described a Q3 loss paired with a revenue beat and GuruFocus flagged record Q3 revenue. BTIG moved in the other direction, raising and then maintaining a $10.00 price target, per GuruFocus.

So today's session combines a sell-side downgrade in target price with a results print that was mixed: top line ahead, bottom line behind. The mechanics of the move are amplified by size and price. At a $0.36 billion market capitalisation and a share price under $5, percentage swings tend to be larger for a given amount of dollar selling. Turnover of 17.3 times the one-month average tells you this was a broad repricing rather than a thin tape drifting, with 23,873,174 shares changing hands. The close at $3.62 leaves the stock 27% of the way up its 52-week band of $2.32 to $7.13, nearer the low end than the high.

Were Insiders Buying or Selling?

Our own Form 4 record shows activity on both sides of the ledger over the last six months. One insider bought on the open market, filing 8 separate purchases worth $687,745 in aggregate, with the most recent dated Fri Aug 14 2026. Our filing record lists Chernett Jorey, in an "Other" insider capacity, as the most recent recorded purchaser.

Against that, two insiders sold, recording 4 disposals worth $2.2 million in total, the latest on Fri Aug 21 2026. On the measured dollar figures, selling outweighed buying by roughly three to one, and the most recent transaction on file was a sale rather than a purchase.

What this does tell a reader is that at least one person with an inside view was willing to commit real money at market prices as recently as August. What it does not tell anyone is why. Form 4 filings disclose the trade, not the thinking behind it, and disposals can reflect tax planning, diversification or pre-set plans as readily as any view on value.

Should You Invest in Starling Oncology, Inc.?

The data here supports a few observations and not much more. A 45.97% single-day drop on 17.3 times average volume is historically associated with a genuine repricing of expectations, in this case following a quarterly EPS miss of $0.06 and a lowered price target from Lake Street Capital. The $10.00 target maintained by BTIG sits well above the current $3.62, which may suggest a wide spread of views on the sell side rather than a settled consensus.

What the data does not establish is whether $3.62 is cheap. At a $0.36 billion market capitalisation, 27% of the way up a $2.32 to $7.13 range, with more insider dollars sold than bought in the last six months, investors may want to monitor subsequent Form 4 filings and the next set of quarterly numbers before drawing conclusions.